Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01I in previously treated Stage IV Squamous NSCLC
NCT06780098Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2025
- Primary completion
- Mar 2032
- Countries
- 11
01
Overview
A Phase 2 trial of raludotatug deruxtecan, ifinatamab deruxtecan in squamous cell carcinoma of the lung (SCCL), sponsored by Merck & Co.. Started May 2025; status: recruiting.
02
Drugs
raludotatug deruxtecanifinatamab deruxtecan
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT06780098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06780098.